With a gain of 100 million from Cominar, businessman George Armoyan acquires 10% of Knight Therapeutics
After making a profit of nearly $100 million in less than two years with Cominar during the pandemic, Montreal businessman George Armoyan is turning his attention to another Quebec company.
Continue ReadingHALIFAX, NS, Nov. 15, 2023 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that it has acquired ownership of, and control over, 28,400 common shares (“Shares”) of Morguard Corporation (“Morguard”).
Continue ReadingHALIFAX, NS, Oct. 25, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that its wholly owned subsidiary has acquired $7,100,000 principal amount of 7.50% Convertible Unsecured Subordinated Debentures (“Convertible Debentures”) of Slate Office REIT (“Slate Office”).
Continue ReadingHALIFAX, NS, Sept. 22, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that Clarke Inc. Master Trust (“Clarke MT”), an entity with whom G2S2 is deemed to be a joint actor, has disposed of 326,000 common shares (“Common Shares”) of Calfrac Well Services Ltd. (“Calfrac”).
Continue ReadingHALIFAX, NS, Sept. 20, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that Clarke Inc. Master Trust (“Clarke MT”), an entity with whom G2S2 is deemed to be a joint actor, has disposed of 489,000 common shares (“Common Shares”) of Calfrac Well Services Ltd. (“Calfrac”).
Continue ReadingHALIFAX, NS, Sept. 19, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces today that its wholly owned subsidiary has increased its ownership of trust units (“Units”) of Slate Office REIT (“Slate Office”) to 14.34% of Slate Office’s outstanding Units.
Continue ReadingHALIFAX, NS, Aug. 19, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that it has acquired ownership of, and control over, an additional $246,000 principal amount of Clarke Inc. Convertible Debentures (“Convertible Debentures”) which, if converted, would entitle G2S2 to 17,904 common shares of Clarke Inc. (“Clarke”) and represent 0.12% of the outstanding common shares of Clarke (“Common Shares”). G2S2 acquired the Convertible Debentures on August 18, 2022, through the facilities of the Toronto Stock Exchange at a price of $989.65 per $1,000 of principal (the “Acquisition”).
Continue ReadingHALIFAX, NS, Aug. 11, 2022 /CNW/ – G2S2 Capital Inc. (“G2S2”) announces that its wholly owned subsidiary has disposed of common shares (“Shares”) of Knight Therapeutics Inc. (“Knight”) and no longer holds over 10% of Knight’s outstanding Shares.
Continue Reading